doripenem
Phase 3Completed 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Pneumonia
Conditions
Pneumonia
Trial Timeline
May 1, 2004 → Oct 1, 2006
NCT ID
NCT00211003About doripenem
doripenem is a phase 3 stage product being developed by Johnson & Johnson for Pneumonia. The current trial status is completed. This product is registered under clinical trial identifier NCT00211003. Target conditions include Pneumonia.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (6)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00986102 | Approved | Completed |
| NCT00211016 | Phase 3 | Completed |
| NCT00211003 | Phase 3 | Completed |
| NCT00210990 | Phase 3 | Completed |
| NCT00210938 | Phase 3 | Completed |
| NCT00229060 | Phase 3 | Completed |
Competing Products
20 competing products in Pneumonia